Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.87 |
| ▸ | CA9 | Q16790 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16492508 | 0.95 | CA12 (0.79) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL16492507 | 0.95 | CA12 (0.79) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL17913100 | 0.93 | CA12 (1.00) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL893905 | 0.86 | CA12 (0.73) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL3767094 | 0.85 | MAPT (1.00) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL5317234 | 0.85 | MAPT (0.77) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL12338982 | 0.85 | MAPT (1.00) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL4085457 | 0.85 | MAPT (0.77) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL22125137 | 0.84 | CA12 (0.76) | CA12CA9MAPTHPGDALDH1A1 | |
| SCHEMBL21761420 | 0.83 | ALDH1A1 (0.69) | CA12CA9MAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822002-B | Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves | 中南大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-108892668-A | Benzsulfamide chalcones derivative, the preparation method and the usage of purine-containing ring | 贵州大学 | 2018-11-27 | — | — | CN | disclosed |
| CN-108822002-A | A kind of method of ultrasonic wave added synthesis N- aryl sulfonic acid amides | 中南大学 | 2018-11-16 | — | — | CN | disclosed |
| CN-106008305-B | A kind of synthetic method of five substitutions 2- amino-pyrroles derivatives | 陕西师范大学 | 2018-05-08 | — | — | CN | disclosed |
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| CN-101094837-A | Novel beta agonists, method for producing the same and their use as drugs | BOEHRINGER INGELHEIM INT (DE) | 2007-12-26 | — | — | CN | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| CN-1056840-C | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| US-5972959-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CA12 3106/4885CA9 2480/4885MAPT 468/4885 |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CA12 3518/4885CA9 2328/4885MAPT 590/4885 |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | ADRB3, ADRB2, ADRB1 | CA12 4593/4885CA9 3827/4885MAPT 4073/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | CA12 3518/4885CA9 2328/4885MAPT 590/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | CA12 4760/4885CA9 3729/4885MAPT 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.